AIRAmed Receives FDA 510(k) Clearance for Its AIRAscore Brain Volumetry Software
Retrieved on:
Tuesday, September 19, 2023
FDA, Data Management, Technology, Mental Health, General Health, Medical Devices, Hospitals, Neurology, Artificial Intelligence, Science, Biotechnology, Software, Other Science, Health, Research, Tissue, Learning, Anatomy, Health care, Neurodegenerative disease, Deep learning, DSM-IV codes, Food and Drug Administration, Pons, Dementia, Woman, Radiology, Parkinson, Teaching hospital, CDC, IT, MRI, Cerebellum, Patient, Myenteric plexus, Physician, Reading, Frontotemporal dementia, Artificial intelligence, Airam Cabrera, CSF, White matter, Ageing, Diagnosis, FTD, Alzheimer's disease, Food, Hippocampus, Disease, Medical imaging
German medical technology company AIRAmed has announced U.S. Food and Drug Administration 510(k) clearance of AIRAscore, a medical image management and processing system providing relevant brain volumetry data to assist physicians in early detection of Alzheimer’s and other dementias.
Key Points:
- German medical technology company AIRAmed has announced U.S. Food and Drug Administration 510(k) clearance of AIRAscore, a medical image management and processing system providing relevant brain volumetry data to assist physicians in early detection of Alzheimer’s and other dementias.
- AIRAscore uses deep learning and artificial intelligence (AI) technology to provide quantitative assessment of brain volume with objectively verifiable data using standard MRI brain scans in as little as five minutes.
- “With AIRAscore, we are now offering physicians a highly precise, quantitative tool for the rapid detection of areas with a brain volume below the normal range.
- The software is extremely affordable and can be configured by a hospital’s or radiology facility’s IT department in less than an hour.